AR061206A1 - Pirido[3,2-e]pirazinas, su uso como inhibidores de la fosfodiesterasa 10, y procesos para prepararlas - Google Patents
Pirido[3,2-e]pirazinas, su uso como inhibidores de la fosfodiesterasa 10, y procesos para prepararlasInfo
- Publication number
- AR061206A1 AR061206A1 ARP070102310A ARP070102310A AR061206A1 AR 061206 A1 AR061206 A1 AR 061206A1 AR P070102310 A ARP070102310 A AR P070102310A AR P070102310 A ARP070102310 A AR P070102310A AR 061206 A1 AR061206 A1 AR 061206A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cyclic radical
- halo
- optionally mono
- polysubstituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Pirido[3,2-e]pirazinas, procesos para prepararlas, preparaciones farmacéuticas que comprenden estos compuestos y al uso farmacéutico de estos compuestos, que son inhibidores de la fosfodiesterasa 10, como compuestos activos para tratar enfermedades de mamíferos, que incluyen a un ser humano, que pueden ser influidos por el uso de los compuesto para inhibir la actividad de la fosfodiesterasa 10 en el sistema nervioso central. Más particularmente, tratamiento de trastornos neurologicos y psiquiátricos, por ejemplo psicosis y trastornos que comprenden déficits cognitivos como síntomas. Reivindicacion 1: Compuestos caracterizados porque formula (1) donde el enlace entre A y N es un enlace simple o un doble enlace, A es C cuando el enlace es un doble enlace y CH cuando el enlace es un enlace simple, m es 0 o 1, n es 0 o 1, donde R1 es R2 se seleccionan independientemente de H, un radical cíclico, alquilo C1-8, opcionalmente mono- o polisustituido con halo, OH, O-alquilo C1-3 y/o un radical cíclico, alquenilo C2-8, opcionalmente mono- o polisustituido con halo, OH, O-alquilo C1-3 y/o un radical cíclico, alquilinilo C2-8, opcionalmente mono- o polisustituido con halo, OH, O-alquilo C1-3 y/o un radical cíclico, un sistema anular carbocíclico saturado, monoinsaturado o poliinsaturado con 3 a 8 átomos o un sistema anular heterocíclico con 5 a 15 átomos anulares, cada uno opcionalmente mono- o poliinsaturado con halo, amino, alquilamino C1-3, di-alquilamino C1-3, nitro, alquilo C1-3, O-alquilo C1-3 y/o un radical cíclico y R3 se selecciona de H, un radical cíclico, N3, CN, R6, OR6, SR6, SOR6, SO2R6, NH(CO)OR6, N((CO)OR6)2, NR6 ((CO)OR6), NH-(C=O)-NH2, NR6-(C=O)-NH2, NR6-(C=O)-NH2, NH-(C=O)-NHR6, NR6-(C=O)-NHR6, NH- SO2R6, N(SO2R6)2 y NR6(SO2R6), donde R6 es en cada caso independientemente, un radical cíclico, alquilo C1-8 ciclo(hetero)alquilo C3-8, alquenilo C2-8, ciclo(hetero)alquenilo C3-8, o alquinilo C2-8, cada uno opcionalmente mono- o polisustituido con halo, OH, O-alquilo C1-3 y/o un radical cíclico, R7, OR7, SR7, NHSO2R7, N(SO2R7) o N(R8)SO2R7, donde R7 es arilo, heteroarilo, arilalquilo C1-5, heteroarilalquilo C1-5, donde arilo es fenilo o naftilo, heteroarilo es un sistema anular heterocíclico aromático de 5 a 5 átomos en el anillo que contiene por lo menos un átomo seleccionado de N, que incluye N-oxido, s y O y donde arilo y heteroarilo están opcionalmente mono- o polisustituidos, con halo, amino, alquilamino C1-3, nitro, alquilo C1-3, O-alquilo C1-3 y/o un radical cíclico y R8 es alquilo C1-5, opcionalmente mono- o polisustituido con halo, OH, O-C1-3 alquilo y/o un radical cíclico, R4 se selecciona de H, halo, un radical cíclico, R9, OH u OR9, NH(C=O)-alquilo C1-3, opcionalmente mono- o polisustituido con halo, OH, O-alquilo C1-3 o/y un radical cíclico, NH2, NHR9 o NR9R10, donde R9 y R10 se seleccionan independientemente de - un radical cíclico, - alquilo C1-6 o ciclo(hetero)alquilo C3-6, opcionalmente mono- o polisustituido con halo, OH, O-alquilo C1-3 y/o un radical cíclico, - arilalquilo-C1-5, donde arilo es fenilo, opcionalmente mono- o polisustituido con halo, amino, alquilamino C1-3, di-alquilamino C1-3, nitro, alquilo C1-3, O-alquilo C1-3 y/o radical cíclico o -NR9R10 juntos forman un anillo de cinco, seis o siete miembros saturado o insaturado que puede contener hasta 3 heteroátomos, con preferencia N, que incluye N-oxido, Sy/u O, opcionalmente mono- o polisustituido con halo, amino, alquilamino C1-3, di-alquilamino C1-3, nitro, alquilo C1-3, O-alquilo C1-3 y/o aril-alquilo C1-5, donde arilo es fenilo, opcionalmente mono- o polisustituido con halo, amino, alquilamino c1-3, di-alquilamino C1-3, nitro, alquilo C1-3, O-alquilo C1-3 y/o un radical cíclico, y R5 se selecciona de H, alquilo C1-5, cicloalquilo C3-6 o (CO)-alquilo C1-5, opcionalmente mono- o poli sustituido con halo, OH, O-alquilo C1-3 y/o un radical cíclico, o sales y derivados aceptables para uso farmacéutico de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80924206P | 2006-05-30 | 2006-05-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061206A1 true AR061206A1 (es) | 2008-08-13 |
Family
ID=38441604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102310A AR061206A1 (es) | 2006-05-30 | 2007-05-29 | Pirido[3,2-e]pirazinas, su uso como inhibidores de la fosfodiesterasa 10, y procesos para prepararlas |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7550465B2 (es) |
| EP (1) | EP2021342A1 (es) |
| JP (1) | JP2009538853A (es) |
| KR (1) | KR20090013834A (es) |
| CN (1) | CN101454324A (es) |
| AR (1) | AR061206A1 (es) |
| AU (1) | AU2007267392A1 (es) |
| BR (1) | BRPI0712132A2 (es) |
| CA (1) | CA2651849A1 (es) |
| CL (1) | CL2007001554A1 (es) |
| CR (1) | CR10358A (es) |
| GT (1) | GT200800265A (es) |
| IL (1) | IL193740A0 (es) |
| MX (1) | MX2008014569A (es) |
| NO (1) | NO20085326L (es) |
| PE (1) | PE20080711A1 (es) |
| RU (1) | RU2008152440A (es) |
| SV (1) | SV2009003048A (es) |
| TW (1) | TW200817400A (es) |
| WO (1) | WO2007137820A1 (es) |
| ZA (1) | ZA200807517B (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200815436A (en) * | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| US8299080B2 (en) * | 2006-12-13 | 2012-10-30 | Aska Pharmaceutical Co., Ltd. | Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor |
| US20090143392A1 (en) * | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Methods of Treating Obesity and Metabolic Disorders |
| US20090143361A1 (en) * | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 |
| JP2011505366A (ja) * | 2007-11-30 | 2011-02-24 | ワイス・エルエルシー | ホスホエステラーゼ１０の阻害剤としてのアリールおよびヘテロアリール縮合イミダゾ［１，５−ａ］ピラジン |
| NZ589571A (en) * | 2008-05-07 | 2012-07-27 | Lundbeck & Co As H | Method for treating cognitive deficits using trans-4-((1r,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine |
| WO2010054253A1 (en) * | 2008-11-07 | 2010-05-14 | Biotie Therapies Gmbh | Triazine derivatives as inhibitors of phosphodiesterases |
| BR112013001302A2 (pt) * | 2010-07-20 | 2017-07-04 | Cyrenaic Pharmaceuticals Inc | métodos de uso de derivados de amida cíclica para tratar distúrbios mediados por receptor de sigma |
| CA2806017C (en) * | 2010-07-20 | 2021-06-29 | Cyrenaic Pharmaceuticals Inc. | Methods of use of cyclic amide derivatives to treat schizophrenia |
| US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
| AU2012219316A1 (en) | 2011-02-18 | 2013-10-03 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A) |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| WO2013034761A1 (en) * | 2011-09-09 | 2013-03-14 | H. Lundbeck A/S | Pyridine compounds and uses thereof |
| MX2014005705A (es) | 2011-11-09 | 2014-09-04 | Abbvie Deutschland | Carboxamidas heterociclicas utiles como inhibidores de fosfodiesterasa del tipo 10a. |
| US20130116241A1 (en) | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
| CA2869730A1 (en) | 2012-04-25 | 2013-10-31 | Takeda Pharmaceutical Company Limited | Nitrogenated heterocyclic compound |
| WO2014010732A1 (ja) * | 2012-07-13 | 2014-01-16 | 武田薬品工業株式会社 | 複素環化合物 |
| US20140045856A1 (en) * | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
| US9464085B2 (en) * | 2012-08-17 | 2016-10-11 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
| WO2014041175A1 (en) | 2012-09-17 | 2014-03-20 | Abbott Gmbh & Co. Kg | Novel inhibitor compounds of phosphodiesterase type 10a |
| WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| US9790203B2 (en) | 2012-11-26 | 2017-10-17 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| US9200005B2 (en) | 2013-03-13 | 2015-12-01 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
| US9163019B2 (en) | 2013-03-14 | 2015-10-20 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
| WO2014142255A1 (ja) | 2013-03-14 | 2014-09-18 | 武田薬品工業株式会社 | 複素環化合物 |
| JP6427491B2 (ja) | 2013-07-03 | 2018-11-21 | 武田薬品工業株式会社 | 複素環化合物 |
| JP6411342B2 (ja) | 2013-07-03 | 2018-10-24 | 武田薬品工業株式会社 | アミド化合物 |
| WO2015006689A1 (en) | 2013-07-12 | 2015-01-15 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression |
| US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
| BR112018010216B1 (pt) | 2015-11-20 | 2024-02-15 | Forma Therapeutics, Inc | Purinonas como inibidores da protease específica da ubiquitina 1 e composição farmacêutica compreendendo os referidos compostos |
| CN111511353A (zh) | 2017-06-21 | 2020-08-07 | 田边三菱制药株式会社 | 耐胃液的控释口服剂型 |
| US20210379061A1 (en) | 2018-09-28 | 2021-12-09 | Takeda Pharmaceutical Company Limited | Balipodect for treating or preventing autism spectrum disorders |
| CN114524808B (zh) * | 2022-02-21 | 2023-10-24 | 深圳市儿童医院 | 一种吡唑衍生物及其作为pde10抑制剂的用途 |
| CN114524806B (zh) * | 2022-02-22 | 2024-09-03 | 深圳市儿童医院 | 一种三氮唑衍生物及其作为pde10抑制剂的用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5055465A (en) * | 1989-05-31 | 1991-10-08 | Berlex Laboratories, Inc. | Imidazoquinoxalinones, their aza analogs and process for their preparation |
| AU657986B2 (en) * | 1991-06-14 | 1995-03-30 | Pharmacia & Upjohn Company | Imidazo(1,5-a)quinoxalines |
| DE19510965A1 (de) * | 1995-03-24 | 1996-09-26 | Asta Medica Ag | Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung |
| IL149106A0 (en) | 2001-04-20 | 2002-11-10 | Pfizer Prod Inc | Therapeutic use of selective pde10 inhibitors |
| US20030032579A1 (en) * | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
-
2007
- 2007-05-18 TW TW096117906A patent/TW200817400A/zh unknown
- 2007-05-24 US US11/753,207 patent/US7550465B2/en not_active Expired - Fee Related
- 2007-05-29 BR BRPI0712132-6A patent/BRPI0712132A2/pt not_active IP Right Cessation
- 2007-05-29 JP JP2009512482A patent/JP2009538853A/ja active Pending
- 2007-05-29 MX MX2008014569A patent/MX2008014569A/es active IP Right Grant
- 2007-05-29 CN CNA2007800193040A patent/CN101454324A/zh active Pending
- 2007-05-29 KR KR1020087031860A patent/KR20090013834A/ko not_active Application Discontinuation
- 2007-05-29 AU AU2007267392A patent/AU2007267392A1/en not_active Abandoned
- 2007-05-29 RU RU2008152440/04A patent/RU2008152440A/ru not_active Application Discontinuation
- 2007-05-29 AR ARP070102310A patent/AR061206A1/es unknown
- 2007-05-29 EP EP07725639A patent/EP2021342A1/en not_active Withdrawn
- 2007-05-29 WO PCT/EP2007/004748 patent/WO2007137820A1/en active Application Filing
- 2007-05-29 CA CA002651849A patent/CA2651849A1/en not_active Abandoned
- 2007-05-30 CL CL2007001554A patent/CL2007001554A1/es unknown
- 2007-05-30 PE PE2007000674A patent/PE20080711A1/es not_active Application Discontinuation
-
2008
- 2008-08-28 IL IL193740A patent/IL193740A0/en unknown
- 2008-08-29 ZA ZA200807517A patent/ZA200807517B/xx unknown
- 2008-10-02 SV SV2008003048A patent/SV2009003048A/es active IP Right Grant
- 2008-10-10 CR CR10358A patent/CR10358A/es not_active Application Discontinuation
- 2008-11-27 GT GT200800265A patent/GT200800265A/es unknown
- 2008-12-19 NO NO20085326A patent/NO20085326L/no not_active Application Discontinuation
-
2009
- 2009-05-19 US US12/454,537 patent/US20090239874A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0712132A2 (pt) | 2012-01-17 |
| SV2009003048A (es) | 2009-02-11 |
| US7550465B2 (en) | 2009-06-23 |
| CR10358A (es) | 2009-01-07 |
| JP2009538853A (ja) | 2009-11-12 |
| CA2651849A1 (en) | 2007-12-06 |
| CN101454324A (zh) | 2009-06-10 |
| TW200817400A (en) | 2008-04-16 |
| PE20080711A1 (es) | 2008-06-14 |
| IL193740A0 (en) | 2009-05-04 |
| US20080027064A1 (en) | 2008-01-31 |
| KR20090013834A (ko) | 2009-02-05 |
| GT200800265A (es) | 2010-07-22 |
| US20090239874A1 (en) | 2009-09-24 |
| RU2008152440A (ru) | 2010-07-10 |
| NO20085326L (no) | 2008-12-19 |
| MX2008014569A (es) | 2008-12-03 |
| WO2007137820A1 (en) | 2007-12-06 |
| CL2007001554A1 (es) | 2008-01-18 |
| EP2021342A1 (en) | 2009-02-11 |
| ZA200807517B (en) | 2009-06-24 |
| AU2007267392A1 (en) | 2007-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061206A1 (es) | Pirido[3,2-e]pirazinas, su uso como inhibidores de la fosfodiesterasa 10, y procesos para prepararlas | |
| AR069510A1 (es) | Arilo y heteroarilo imidazo[1,5-a]pirazinas fusionadas como inhibidores de la fosfodiesterasa 10 | |
| AR060984A1 (es) | Derivados de imidazo[1,5-a]pirido[3,2-e]pirazinas,y su uso en el sistema nervioso central como inhibidores de la fosfodiesterasa 10. | |
| AR084457A1 (es) | Derivados de biciclo[3,2,1]octilamida | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| AR079327A1 (es) | Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida | |
| PE20201165A1 (es) | Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| BR112015015812A2 (pt) | derivados de pirimidina fundidos a pirido ou pirrolo como inibidores de autotaxina para tratamento de dor | |
| PE20060630A1 (es) | Amidas sustituidas de acido tienopirrolcarboxilico, amidas del acido pirrolotiazolcarboxilico y analogos relacionados como inhibidores de la caseina cinasa ie | |
| AR074435A1 (es) | Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer. | |
| ECSP099461A (es) | Compuesto heteromonocíclico y uso del mismo | |
| AR080785A1 (es) | Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros. | |
| PE20120209A1 (es) | DERIVADOS DE IMIDAZO-[1,2-a]-PIRAZOLO [4,3-e]PIRIMIDINA O PIRIMIDO-[1,2-a]-PIRAZOLO [4,3-e]PIRIMIDINA COMO INHIBIDORES DE FOSFODIESTERASA 1 (PDE1) | |
| AR065015A1 (es) | Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR055774A1 (es) | Fenilacetamidas apropiadas como inhibidores de proteina quinasa | |
| AR097431A1 (es) | Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim | |
| AR101174A1 (es) | Imidazopirazinas como inhibidores de lsd1 | |
| CY1108908T1 (el) | Ενωσεις κινολινονης - καρβοξαμιδης ως αγωνιστες υποδοχεων 5-ητ4 | |
| AR079541A1 (es) | Compuestos sustituidos de n-(1h-indazol-4-il) imidazo (1,2-a) piridin-3-carboxamida como inhibidores de cfms | |
| AR060316A1 (es) | Azaindoles de utilidad como inhibidores de janus quinasas | |
| PE20190339A1 (es) | 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1 | |
| AR057131A1 (es) | Derivados de purina como inmunomodulador | |
| PE20090556A1 (es) | DERIVADOS DE 6-CICLOAMINO-3-(PIRIDIN-4-IL) IMIDAZO [1,2-b]-PIRIDAZINA COMO INHIBIDORES DE CASEINA QUINASAS Y SU PREPARACION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |